Cosmetic cross-reference

40516-49-2

CAS 40516-49-2

40516-49-2 (CAS 40516-49-2) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
40516-49-2
CAS Number
40516-49-2
UNII
0WN694NBMM
InChIKey
RIQIJXOWVAHQES-UNAKLNRMSA-N
ChEMBL ID
CHEMBL262520
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
TOCOPHERYL RETINOATE
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 5725.5 nM 1 -
SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
TOCOPHERYL RETINOATE 1313259 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 40516-49-2 used for in pharmaceutical contexts?

40516-49-2 (CAS 40516-49-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 40516-49-2?

No adverse-event association or SIDER side-effect rows are rendered for 40516-49-2 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 40516-49-2 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Tocopheryl Retinoate with EU status "permitted".

What clinical phase is 40516-49-2 in?

No phase 1-4 clinical development badge is rendered for 40516-49-2 because the matched compound identifier rows do not contain a max-phase value.